|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Results of a European organization for research and treatment of cancer/early clinical studies group phase Ⅱ trial of first-line irinotecan in patients with advanced or recurrent squarnous cell carcinoma of the cervix显示文摘 | Lhommé C Fumoleau P Fargeot P | 1999 | J Clin Oncol1999，17，10： | 1 |
| 2 | Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer显示文摘 | Muriel Arnal Noreli Franco Pierre Fargeot Jean-Marc Riedinger Patrick Brunet-Lecomte Sarab Lizard-Nacol | 2000 | Breast Cancer Research and Treatment2000，，1： | 1 |
| 3 | Results of a European Organization for research and treatment of cancer/Early Clinical Studies Group phase Ⅱ trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix显示文摘 | Lhommé C Fumoleau P Fargeot P | 1999 | J Clin Oncol1999，17，10： | 1 |
| 4 | New applications of acoustic emission technique for real-time monitoring of material processes显示文摘 | T. J. Chotard A. Smith N. Codet M. De Baillencourt D. Fargeot C. Gault | 2002 | Journal of Materials Science Letters2002，，16： | 1 |
| 5 | Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial 显示文摘 | Fargeot P Bonneterre J Roche H | 2004 | J Clin Oncol2004，22，23： | 1 |
| 6 | Nonlinear observers for chemical reactors 显示文摘 | Hammouri H Celle F | 1994 | Chem Eng Sci1994，49，4： | 1 |
| 7 | Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer 显示文摘 | Franco N Fargeot P | 2000 | Breast Cancer Res Treat2000，，： | 1 |
| 8 | Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase Ⅱ trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix显示文摘 | Lhomme C Fumoleau P Fargeot P | 1999 | J Clin Oncol1999，17，10： | 1 |
| 9 | Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable,node-positive,elderly breast cancer patients:6-year follow-up results of the French adjuvant study group 08 trial显示文摘 | Fargeot P Bonneterre J Roch E H | 2004 | J Clin Oncol2004，22，23： | 1 |
| 10 | Enhancement of mdr 1 gene expression in normal tissue adjacent to advanced breast cancer 显示文摘 | Arnal M Franco N Fargeot P | 2000 | Breast Cancer R Treat2000，61，1： | 1 |
| 11 | Result s of a EuropeanOrganization for Research and Treatment of Cancer/ Early Clinical Studies Group phase Ⅱtrial of first2line irinotecan in patient swit h advanced or recurrent squamous cell carcinoma of t he cervix显示文摘 | L homme C Fumoleau P Fargeot P | 1999 | J Clin Oncol1999，17，10： | 1 |
| 12 | Enhancement of mdrl gene expression in normal tissue adjacent to advanced breast cancer 显示文摘 | Amal M Franco N Fargeot P | 2000 | Breast Cancer Res Treat2000，61，1： | 1 |
| 13 | Enhancement of mdr1 gene expression in normal tissue adjacent to advanced breast cancer显示文摘 | Arnal M Tranco N Fargeot P | 2000 | Breast Cancer Res Treat2000，61，1： | 1 |
| 14 | Yttrium SiAION glasses :structure and mechanical properties-elasticity and viscosity 显示文摘 | LEMERCIER H ROUXEL T FARGEOT D | 1996 | J Non-Cyst Solids1996，201，12： | 1 |
| 15 | Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable', node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial 显示文摘 | Fargeot P Bonneterre J Roch6 H | 2004 | J Clin Oncol2004，22，23： | 1 |
| 16 | Ultrasonic investigation of the time-dependent damage in a 2D SiC/SiC composite understatic loading 显示文摘 | CHEVALIER J HUGER M FARGEOT D | 1998 | J Eur Ceram Soc1998，18，13： | 1 |
| 17 | Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-years follow-up results of the French adjuvant study group 08 trial 显示文摘 | Fargeot P Bonneterre J RochO H | 2004 | J Clin Oncol2004，22，23： | 1 |
| 18 | Yttrium SiAlON glasses:structure and mechanical properties-elasticity andviscosity显示文摘 | Lemercier H Rouxel T Fargeot D | | 0，，201： | 1 |
| 19 | Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable,node-positive,elderly breast cancer patients:6-years follow-up results of the French Adjuvant Study Group 08 trial 显示文摘 | FARGEOT P BONNETERRE J ROCHE H | 2004 | J Clin Oncol2004，22，23： | 1 |
| 20 | Results of a Euro-pean Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irino-tecan in patients with advanced or recurrent squamous cellcarcinoma of the cervix显示文摘 | Lhomm C Fumoleau P Fargeot P | 1999 | J Clin Oncol1999，17，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员